Showing 1 - 6 results of 6 for search 'Maria Lajer', query time: 0.04s
Refine Results
-
1
Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. by Jakob S Knudsen, Lisbeth M Baggesen, Maria Lajer, Larisa Nurkanovic, Anastasia Ustyugova, Henrik T Sørensen, Reimar W Thomsen
Published 2020-01-01
Article -
2
Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes by Simone Theilade, Christian Stevns Hansen, Tine W Hansen, Theis Bjerre-Christensen, Signe A Winther, Nete Tofte, Tarunveer S Ahluwalia, Maria Lajer
Published 2021-03-01
Article -
3
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness St... by Reimar W. Thomsen, Jakob S. Knudsen, Johnny Kahlert, Lisbeth M. Baggesen, Maria Lajer, Pia H. Holmgaard, Ola Vedin, Anastasia Ustyugova, Henrik T. Sørensen
Published 2021-06-01
Article -
4
Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism by Christian S. Hansen, Tommi Suvitaival, Simone Theilade, Simone Theilade, Simone Theilade, Ismo Mattila, Maria Lajer, Kajetan Trošt, Linda Ahonen, Tine W. Hansen, Cristina Legido-Quigley, Peter Rossing, Peter Rossing, Tarunveer S. Ahluwalia, Tarunveer S. Ahluwalia
Published 2022-04-01
Article -
5
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes... by Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad, Maria Lajer, Christina Shay, Lisette Koeneman, Soulmaz Fazeli Farsani, Leo Niskanen, Sigrun Halvorsen
Published 2024-01-01
Article -
6
New susceptibility loci associated with kidney disease in type 1 diabetes. by Niina Sandholm, Rany M Salem, Amy Jayne McKnight, Eoin P Brennan, Carol Forsblom, Tamara Isakova, Gareth J McKay, Winfred W Williams, Denise M Sadlier, Ville-Petteri Mäkinen, Elizabeth J Swan, Cameron Palmer, Andrew P Boright, Emma Ahlqvist, Harshal A Deshmukh, Benjamin J Keller, Huateng Huang, Aila J Ahola, Emma Fagerholm, Daniel Gordin, Valma Harjutsalo, Bing He, Outi Heikkilä, Kustaa Hietala, Janne Kytö, Päivi Lahermo, Markku Lehto, Raija Lithovius, Anne-May Osterholm, Maija Parkkonen, Janne Pitkäniemi, Milla Rosengård-Bärlund, Markku Saraheimo, Cinzia Sarti, Jenny Söderlund, Aino Soro-Paavonen, Anna Syreeni, Lena M Thorn, Heikki Tikkanen, Nina Tolonen, Karl Tryggvason, Jaakko Tuomilehto, Johan Wadén, Geoffrey V Gill, Sarah Prior, Candace Guiducci, Daniel B Mirel, Andrew Taylor, S Mohsen Hosseini, DCCT/EDIC Research Group, Hans-Henrik Parving, Peter Rossing, Lise Tarnow, Claes Ladenvall, François Alhenc-Gelas, Pierre Lefebvre, Vincent Rigalleau, Ronan Roussel, David-Alexandre Tregouet, Anna Maestroni, Silvia Maestroni, Henrik Falhammar, Tianwei Gu, Anna Möllsten, Danut Cimponeriu, Mihai Ioana, Maria Mota, Eugen Mota, Cristian Serafinceanu, Monica Stavarachi, Robert L Hanson, Robert G Nelson, Matthias Kretzler, Helen M Colhoun, Nicolae Mircea Panduru, Harvest F Gu, Kerstin Brismar, Gianpaolo Zerbini, Samy Hadjadj, Michel Marre, Leif Groop, Maria Lajer, Shelley B Bull, Daryl Waggott, Andrew D Paterson, David A Savage, Stephen C Bain, Finian Martin, Joel N Hirschhorn, Catherine Godson, Jose C Florez, Per-Henrik Groop, Alexander P Maxwell
Published 2012-09-01
Article